Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ACACB | O00763 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | PHGDH | O43175 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16151531 | 0.87 | GRM5 (0.57) | GRM5HPGDSMN1; SMN2ACACBALDH1A1 | |
| SCHEMBL3644132 | 0.86 | EPHX2 (0.66) | GRM5HPGDSMN1; SMN2ACACBEPHX2 | |
| SCHEMBL3644126 | 0.85 | GRM5 (0.71) | GRM5HPGDSMN1; SMN2ACACBPHGDH | |
| SCHEMBL3637719 | 0.84 | PHGDH (0.56) | GRM5HPGDSMN1; SMN2ACACBEPHX2 | |
| SCHEMBL3640225 | 0.84 | GRM5 (0.74) | GRM5SMN1; SMN2 | |
| SCHEMBL16151537 | 0.84 | ACACB (0.56) | GRM5SMN1; SMN2ACACB | |
| SCHEMBL16151532 | 0.82 | GRM5 (0.74) | GRM5HPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL3642899 | 0.81 | GRM3 (0.63) | GRM5SMN1; SMN2ACACB | |
| SCHEMBL4712558 | 0.81 | GRM5 (0.65) | GRM5ACACBKDM4EALDH1A1 | |
| SCHEMBL3637206 | 0.81 | GRM5 (0.55) | GRM5SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853392-B2 | Benzamide mGluR5 positive allosteric modulators and methods of making and using same | VANDERBILT UNIVERSITY (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853392-B2 | Benzamide mGluR5 positive allosteric modulators and methods of making and using same | VANDERBILT UNIVERSITY (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853392-B2 | Benzamide mGluR5 positive allosteric modulators and methods of making and using same | VANDERBILT UNIVERSITY (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2162136-A1 | BENZAMIDE MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20090042855-A1 | BENZAMIDE mGluR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | DEPARTMENT OF VETERANS AFFAIRS | 2009-02-12 | — | — | US | disclosed |
| US-20090042855-A1 | BENZAMIDE mGluR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | DEPARTMENT OF VETERANS AFFAIRS | 2009-02-12 | — | — | US | disclosed |
| WO-2008151184-A1 | BENZAMIDE MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008151184-A1 | BENZAMIDE MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY (US) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042855-A1 | BENZAMIDE mGluR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | GRM5, GRIK5, GRM3 | GRM5 1/4885HPGD 3544/4885SMN1; SMN2 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.